The European Health Data Space: New Rights for Patients, New Access to Data for Research and Innovation

Health data are among the most valuable and most sensitive data in the economy. They are also fragmented across hospitals, laboratories, insurers, registries and devices, often in incompatible formats. The European Health Data Space Regulation (Regulation (EU) 2025/327), in force since 26 March 2025, is the first sectoral data space established by EU law. We introduced common European data spaces in [LINK – previous article on data spaces]. The EHDS gives patients new rights over their health records, sets new requirements for electronic health record systems, and opens a structured route through which researchers, public authorities and companies can access health data for research and innovation.
Implementation has now entered a more concrete phase. In September 2026 the Commission adopted three implementing regulations, bringing the number of EHDS implementing acts adopted to four. In October it consulted on the templates that will govern access to data for secondary use. With general application set for 26 March 2027, companies have less time than the later deadlines may suggest.
1. Two pillars: primary and secondary use
The Regulation distinguishes two forms of use:
- Primary use: the use of health data to provide care to the person concerned.
- Secondary use: the reuse of health data for research, innovation, policy-making, official statistics, patient safety, regulatory activities and similar purposes.
Each pillar has its own rules, infrastructure and timeline. The Regulation applies generally from 26 March 2027, but most key provisions apply later, in stages:
- 26 March 2029: the rules on secondary use, together with the first group of priority categories for primary use (patient summaries, electronic prescriptions and dispensations);
- 26 March 2031: the second group of priority categories (medical images, laboratory results and discharge reports), and secondary use of certain further categories of data.
2. New rights for patients
Patients will have the right to access their electronic health data immediately and free of charge through electronic access services. They will also be able to:
- add information;
- request rectification;
- restrict access by health professionals;
- know who has accessed their data;
- share them with other providers, including in another Member State through the MyHealth@EU infrastructure.
Priority categories must be exchanged in a common European format. The operational framework for MyHealth@EU is now set out in Implementing Regulation (EU) 2026/2083, which applies from 26 March 2027. It covers central services, technical specifications, cybersecurity and the conditions for national contact points to connect. Implementing Regulation (EU) 2026/2099 establishes a common mechanism for the cross-border identification and authentication of patients, health professionals and providers, linked to the European Digital Identity framework. Member States must define the national healthcare attributes by 26 March 2028.
Consequences for EHR manufacturers
These rights have direct consequences for the market. Manufacturers of electronic health record systems will have to comply with essential requirements on interoperability and logging, self-certify their systems and affix CE marking. For software companies active in healthcare, this is a product compliance regime comparable to those in other EU product legislation. Where the software also has other digital elements, or integrates AI, it will have to be coordinated with the Cyber Resilience Act and the AI Act.
3. New access to data: data permits for research and innovation
The most innovative part of the Regulation concerns secondary use. Health data holders will have to make categories of electronic health data available through national health data access bodies. Data holders include hospitals, research institutions, registries and companies in the health and care sector, with an exception for micro-enterprises.
A data user may be a researcher, a public body or a company. It submits an application describing the purpose, the data needed and the safeguards. If the requirements are met, the access body issues a data permit. The data are then made available in a secure processing environment, anonymised by default, or pseudonymised where the purpose requires it. Only non-personal results may leave the environment. Users who need only statistics or aggregated analyses can follow a lighter route, the health data request, without direct access to the datasets.
The practical tools are now taking shape:
- Dataset metadata. Implementing Regulation (EU) 2026/2098, applicable from 26 March 2029, sets the minimum metadata that data holders must provide to describe their datasets, based on the HealthDCAT-AP standard. The aim is machine-readable national catalogues that can be linked through a future EU dataset catalogue.
- Access templates. The Commission has consulted on a draft implementing act under Article 70 setting standard templates for the data access application, the data permit and the health data request. The act is due to be adopted by March 2027.
- Access bodies. Each Member State must designate its access body or bodies by 26 March 2027. The cross-border infrastructure HealthData@EU will connect them.
The Regulation lists permitted purposes and prohibits others. Prohibited uses include:
- taking decisions detrimental to individuals;
- excluding people from insurance or credit, or changing its terms;
- advertising or marketing activities;
- developing products or services that may harm individuals or society, such as illicit drugs, alcohol or tobacco;
- activities that conflict with ethical provisions of national law;
- making the data available to third parties not named in the data permit.
Ask: are we a health data holder that will have to make data available, a potential data user, or both? Which of our datasets fall within the categories of the Regulation, and are they described well enough to meet the new metadata requirements?
4. Opt-out, GDPR and trade secrets
Individuals will have the right to opt out of the secondary use of their health data, through an accessible mechanism and without having to give reasons. Member States may provide for limited exceptions for certain public interest purposes. The Regulation does not replace the GDPR. Data users must still show a legal basis under Article 6 GDPR, while the EHDS itself is meant to meet the conditions of Article 9(2) for the permitted secondary uses. The access body checks these elements when it assesses the application.
Data holders’ rights are also protected. Data covered by intellectual property rights or trade secrets can be made available only with measures to preserve their confidentiality. The access body may refuse access where the risk cannot be adequately addressed. This matters for medical device manufacturers, pharmaceutical companies and clinical research organisations, whose datasets may fall within the scope of the Regulation. As under the Data Act, which we discussed in Data Act: can you charge for sharing data, and how much?, data holders will need to identify in advance which data are confidential and how they can be protected.
5. Health data and AI
The EHDS is expected to become an important source of data for training, validating and testing AI systems in healthcare. Secondary use for the development of AI, including medical devices and digital health applications, is among the permitted purposes. For high-risk systems, the data obtained will have to meet the quality requirements of Article 10 of the AI Act, which we examined in AESIA Guidelines on the AI Act – Guide No. 7: Data and Data Governance.
Training on health data also raises questions about what happens to personal data once a model has been trained. The Italian Data Protection Authority addressed this point in its opinion on AI training in the Province of Trento, discussed in Un modello di IA può dimenticare? (in Italian). The anonymised-by-default approach and the secure processing environment of the EHDS are designed precisely to reduce these risks.
6. The Italian context
Italy is preparing through the Fascicolo Sanitario Elettronico 2.0 and the national health data ecosystem (Ecosistema Dati Sanitari) funded under the PNRR. Implementation of the EHDS is now coordinated through dedicated structures:
- Steering committee. A Ministry of Health decree of 20 February 2026 established a national Cabina di regia, which was installed on 5 May 2026. It brings together the Ministry, the Ministry of Economy and Finance, AGENAS, the Istituto Superiore di Sanità, AIFA, ISTAT, the Department for Digital Transformation, AgID and the Regions.
- Technical groups. Four technical groups were set up in July 2026. The one on secondary use is coordinated by AGENAS.
- Access bodies. According to the Ministry’s delegate to the EHDS Committee, the design under development provides for four health data access bodies: the Ministry of Health, the Istituto Superiore di Sanità, AGENAS and ISTAT. The final designation must be notified to the Commission by March 2027.
In parallel, Article 8 of Law No. 132/2025 has declared processing for research and experimentation aimed at developing AI systems in healthcare to be of substantial public interest. This allows the secondary use of data without direct identifiers without new consent, subject to three conditions: general information on the controller’s website, approval by an ethics committee, and prior communication to the Garante. The Garante has thirty days to block the processing; if it does not, processing may begin. Commentators have noted that this regime lacks some safeguards of the EHDS, such as the individual opt-out and the list of prohibited purposes. The two frameworks will have to be coordinated, and Italy’s implementing measures will show how.
Where to start
Companies in the health sector should take five steps now:
- determine whether they are data holders, data users or manufacturers of electronic health record systems, or more than one of these;
- inventory the datasets that may fall within the Regulation and start describing them according to the new metadata standard;
- identify the trade secrets and intellectual property that need protection, and the measures they will ask the access body to apply;
- prepare for the interoperability, logging and certification requirements for electronic health record systems;
- for those developing AI, consider the data permit as a future route to training and validation data, alongside the Italian rules on research, and plan how the two will fit together.
The practical question is not “can we get health data?” It is: under which permit, for which purpose, and with which safeguards for patients and for our own secrets can we use them?
Data Valley supports companies, research organisations and healthcare providers in preparing for the EHDS, from dataset mapping and data governance to the protection of trade secrets, GDPR compliance and the use of health data for AI development. We have worked on health data sharing since our 2022 e-Health Data Sharing White Paper, and we follow the national and European implementation closely.
Sei pronto a trasformare i dati in valore per il tuo business?

